YONMEZI Trademark

Trademark Overview


On Thursday, May 13, 2021, a trademark application was filed for YONMEZI with the United States Patent and Trademark Office. The USPTO has given the YONMEZI trademark a serial number of 90710085. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Wednesday, October 23, 2024. This trademark is owned by Celgene Corporation. The YONMEZI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical pre...
yonmezi

General Information


Serial Number90710085
Word MarkYONMEZI
Filing DateThursday, May 13, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateWednesday, October 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 30, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 12, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Thursday, January 20, 2022NON-FINAL ACTION E-MAILED
Monday, May 17, 2021NEW APPLICATION ENTERED
Thursday, August 12, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, January 20, 2022ASSIGNED TO EXAMINER
Thursday, January 20, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 18, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 18, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 20, 2022NON-FINAL ACTION WRITTEN
Monday, July 18, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 28, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, July 28, 2022EXAMINERS AMENDMENT -WRITTEN
Thursday, July 28, 2022EXAMINERS AMENDMENT E-MAILED
Thursday, July 28, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, July 28, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, August 10, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 30, 2022PUBLISHED FOR OPPOSITION
Tuesday, August 30, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 25, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, April 6, 2023SOU TEAS EXTENSION RECEIVED
Thursday, April 6, 2023SOU EXTENSION 1 FILED
Thursday, April 6, 2023SOU EXTENSION 1 GRANTED
Thursday, March 14, 2024SOU TEAS EXTENSION RECEIVED
Saturday, April 8, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 11, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, October 11, 2023SOU EXTENSION 2 FILED
Wednesday, October 11, 2023SOU EXTENSION 2 GRANTED
Friday, October 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 14, 2024SOU EXTENSION 3 FILED
Friday, March 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 23, 2024SOU EXTENSION 4 FILED
Thursday, March 14, 2024SOU EXTENSION 3 GRANTED
Wednesday, October 23, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, October 23, 2024SOU EXTENSION 4 GRANTED
Wednesday, April 9, 2025SOU TEAS EXTENSION RECEIVED